相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study
Giorgio Bolis et al.
EUROPEAN JOURNAL OF CANCER (2010)
Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer
Helen J. Mackay et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer
Andreas du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin-Topotecan and Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel
P. Hoskins et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
Michael A. Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1
Sergio Pecorelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
Noriyuki Katsumata et al.
LANCET (2009)
Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial
S. Pignata et al.
ONCOLOGY (2009)
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
Richard W. Tothill et al.
CLINICAL CANCER RESEARCH (2008)
Stemness genomics law governs clinical behavior of human cancer: Implications for decision making in disease management
Gennadi V. Glinsky
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III Randomized trial of intravenous cisplatin plus a 24-or 96-hour infusion of paclitaxel in epithelial ovarian cancer: gynecologic oncology group study
David R. Spriggs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
Lucy Gossage et al.
CANCER TREATMENT REVIEWS (2007)
Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer:: Intergroup trial of the AGO-Ovar/AIO and EBMT
Volker Moebus et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study
William E. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer:: A gynecologic cancer intergroup trial of the AGO-OVAR and GINECO
Jacobus Pfisterer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness
Paul P. Szotek et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
A du Bois et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study
G Bolis et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Epithelial-mesenchymal transition in development and cancer:: role of phosphatidylinositol 3′ kinase/AKT pathways
L Larue et al.
ONCOGENE (2005)
Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations
G Pohl et al.
CANCER RESEARCH (2005)
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis -: A mutational analysis with immunohistochemical correlation
G Singer et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment
V Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
PA Vasey et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian trials in ovarian cancer (MITO-1) randomized study
S De Placido et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy
MJ Piccart et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2003)
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin
GB Kristensen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2003)
Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia
AD Guminski et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
分享论文
